Owners of policies sold in the ‘80s and ‘90s face steeper-than-expected premiums
The 156-year old insurer’s move marks a major shift toward technology
Experts argue that current policies overly favour private insurers and drug companies
Insurers will have to deal with new risk and coverage issues as use of the substance becomes more prevalent
Only 25 out of 102 have answered a Health Canada request to stop marketing to healthcare professionals
The firm is arguing that MetLife, which originally sold the policies, should be held accountable
Teaser: High-cost medications and reduced generics savings continue to weigh on public plans
A barrier protecting brand-name drugs from generic competition could become considerably higher